New Delhi | February 16, 2026: Mankind Pharma, India’s fourth-largest pharmaceutical company, has completed a multi-year transformation of its global supply chain and strategic procurement function in collaboration with Accenture. The initiative embeds digitally enabled operating models, powered by advanced analytics and AI, across procurement, manufacturing, and distribution networks, enhancing the company’s ability to manage demand volatility, supply disruptions, and regulatory complexities at scale.
Transformation Highlights
- Integrated Planning Platform: Connects demand forecasting, manufacturing, inventory, and distribution across 25+ international markets in near real-time.
- AI-Augmented Insights: Strengthened forecast accuracy, improved cross-functional alignment, and enabled faster, more responsive planning.
- Procurement Overhaul: Standardized processes, digital automation, and analytics-led decision-making reinforced cost discipline, governance, and supplier collaboration.
- Operational Impact:
- Reduced drug stock-outs by 75%.
- Optimized inventory by up to 20% across 30 manufacturing facilities and 50+ distribution centers.
- Improved coordination across commercial, manufacturing, and supply teams.
Arjun Juneja, COO, Mankind Pharma Ltd., said: “Ensuring uninterrupted access to quality medicines requires value chains that are intelligent, digitally enabled, and resilient by design. At Mankind, we have reimagined the traditional value chain into a life chain, built to serve patients, not just processes. This transformation delivers sharper visibility, stronger control, and quality by design, enabling us to scale responsibly while reinforcing our commitment to Availability, Quality, and Affordability.”
Jignesh Vora, Managing Director & Lead – Life Sciences, Accenture India, added: “Working closely with Mankind Pharma, we helped reimagine and strengthen its operating model for the long term. By combining AI-led, data-driven capabilities with deep life sciences expertise, we enabled a predictive and resilient supply chain and procurement ecosystem – improving access to medicines and supporting sustainable growth in a volatile environment.”
Strategic Outcomes
- Supply Chain Resilience: Unified backbone linking planning intelligence with execution performance.
- Procurement Excellence: Elevated sourcing as a core business capability, with digital tools automating routine tasks and analytics enhancing visibility into spending and supplier performance.
- Sustainable Growth: Delivered cost efficiencies while safeguarding quality, compliance, and supply continuity.
About Mankind Pharma
Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of India’s largest pharmaceutical companies, with a strong domestic presence across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynecology, VMN, and respiratory.
In consumer healthcare, Mankind operates in categories such as condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements, and anti-acne preparations, with several category-leading brands. Following the acquisition of Bharat Serums and Vaccines Limited, Mankind has further strengthened its leadership in women’s health.
The company’s distribution network includes 17,700+ professionals, reaching over five lakh doctors across India. With 32 manufacturing facilities and 6 dedicated R&D centers backed by 730+ scientists, Mankind continues to innovate across dosage forms including tablets, capsules, syrups, vials, ampoules, gels, eye drops, creams, contraceptives, and OTC products.
🌐 Website: www.mankindpharma.com
